Arrowhead Pharmaceuticals to Present Detailed Phase 3 Results for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals is scheduled to present detailed 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran, a treatment for severe hypertriglyceridemia, at the European Society of Cardiology (ESC) Congress 2026. The presentation will take place on August 30, 2026, as part of a 'HOT LINE Late-Breaking Science Session,' marking a significant update on the clinical trial findings.